CARDIOPROGRESS
Foundation for the advancement of cardiology

Congenital heart disease in England: a national cohort study from fetal diagnosis to end of infancy Population-based studies of congenital heart defects (CHDs) often include only children who have undergone cardiac surgery, leading to an underestimation of the number of cases that do not require intervention. In a new study, the authors analyzed the outcomes of all identified cases of structural CHDs in England from prenatal to one year of age.

Younger Age Offers No Protection From HFrEF Deaths Patients aged 40-85 years with heart failure with reduced ejection fraction (HFrEF) died at higher rates over 5 years than matched peers from the general population across all age groups; however, the greatest relative impact was seen in younger adults (aged 40-49 years).

Atopic Dermatitis in Childhood Not Linked to Early Cardiovascular Risk In a UK study of 9281 participants followed from childhood into early adulthood, atopic dermatitis, including more active and severe atopic dermatitis, was not consistently associated with cardiometabolic risk scores, traditional cardiovascular risk factors (blood pressure, lipid profiles), or measures of subclinical atherosclerosis.

Changes in Physical Activity Following Heart Failure in Humans and Animal Models: A Scoping Review According to a review, patients with heart failure (HF) experience decreased physical activity (PA) due to fatigue, shortness of breath, and psychological and environmental factors. This leads to a decline in physical function and prognosis, but the extent of the decline in PA specifically due to heart failure remains unclear.

Toward Personalized Heart Failure Management: Integrating Biomarkers and Multimodal Monitoring Strategies Scientists have discovered that effective treatment of heart failure (HF) requires timely detection and treatment of congestive heart failure in both inpatient and outpatient settings. As HF treatment approaches become more complex, interest in improved therapeutic strategies, including biomarker-based approaches and noninvasive and invasive remote monitoring methods, is growing.

Factor XI Inhibitor Abelacimab Cuts Bleeding Risk Across Age Groups in Atrial Fibrillation Among adults with atrial fibrillation (AF), those who received the factor XI inhibitor abelacimab had a lower risk for major or clinically relevant nonmajor bleeding than those who received the oral anticoagulant rivaroxaban across age groups, with greater absolute risk reductions in older adults.

High Salivary Aldosterone Can Signal Future Heart Disease Researchers cross-sectionally compared the salivary free AldAR among men with coronary heart disease, essential hypertension, and normotension and prospectively evaluated whether the AldAR could predict the risk for coronary heart disease.

Weight Gain Risks: The Ultraprocessed Food Connection Researchers analyzed data from 24,453 Brazilian adults (79.7% women) in the NutriNet Brasil cohort study, who were followed up for a median of 43.6 months, to assess the association between consumption of ultraprocessed foods and weight gain.

Low Vitamin D Levels Signal Increased Heart Risk in Seniors In older adults, lower levels of vitamin D metabolites and periostin, a protein involved in remodelling and repairing tissues, were linked to an increased cardiovascular (CV) risk. Low periostin levels were correlated with low vitamin D levels, and when all three markers were considered together, only the active form of vitamin D independently predicted the CV risk.

Mapping the evidence on mHealth interventions for cardiovascular event care in Africa: a scoping review The burden of cardiovascular disease in Africa is projected to increase significantly over the next decade, placing additional strain on already overburdened healthcare systems. Mobile health (mHealth) technologies represent a promising approach to addressing these challenges. This review analyzes the use of mHealth solutions in cardiovascular care in Africa.

Simulation deficit in cardiology training: a missed opportunity for the modern trainee Cardiology training today exists in a paradox. As the specialty becomes more complex, particularly in procedural domains, the time and resources available to train new cardiologists have dwindled. Simulation has become an increasingly important component of modern cardiology training, offering a safe, structured and reproducible environment in which clinical skills can be developed and refined.1 The term simulation encompasses a broad spectrum of educational approaches, ranging from focused task training to high-fidelity scenario-based learning.

Shingles vaccine protects against cardiovascular diseases Shingles vaccination reduced major adverse cardiac events and secondary cardiovascular outcomes for patients with atherosclerotic cardiovascular disease, according to new research.

Nobel Prize in Physiology or Medicine 2025 The Nobel Prize in Physiology or Medicine 2025 was awarded to Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi "for their discoveries concerning peripheral immune tolerance.

World Heart day 2025 World Heart Day is celebrated annually on September 29. Since its inception, the Cardioprogress Foundation has actively collaborated with the World Heart Federation and, to celebrate this occasion, organizes events in various cities across the Russian Federation.

EASD to Feature Major Trial Results, Clinical Guidance The European Association for the Study of Diabetes (EASD) 2025 Annual Meeting will feature major clinical trial results in type 2 diabetes (T2D), type 1 diabetes (T1D), obesity, several new clinical practice guidelines, and much more.

2025 ESC Congress HOT LINE sessions: key clinical studies From August 29 to September 1, 2025, the regular Congress of the European Society of Cardiology was held in Madrid (Spain), combined this year with the World Congress of Cardiology. The main theme of the event was "Global Health: Cardiology Without Borders".
This event brought together leading experts and researchers from different countries and allowed them to discuss new research and achievements in the treatment of cardiovascular diseases.

Cardioprogress Newsletter Dear Colleagues!
The Cardioprogress Foundation resumes publishing a quarterly newsletter dedicated to scientific news in cardiology. If you are interested in specific topics and details of scientific discoveries in the field of cardiology, please write to us. (The e-mail address is indicated on the last page of the newsletter).

Baxdrostat: A “Game Changer” for Hypertension? A new class of antihypertensive agent that blocks the production of aldosterone — a key hormone believed to drive increased blood pressure — has shown impressive results in one of the first pivotal phase 3 trials in patients with resistant or uncontrolled hypertension.

ACC Recommends Vaccination Against Respiratory Illness in Cardiovascular Disease Adults with heart disease should get vaccinated against a range of respiratory viruses, according to new clinical guidance from the American College of Cardiology.

New Type 2 Diabetes Guidance Ties Treatment Choice to Cardio-Renal Risk New guidance on preventing cardiovascular (CV) and renal complications in type 2 diabetes (T2D) emphasizes tailoring therapy to a patient’s individual risk profile.